Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients

Journal of Nuclear Medicine

Volumn 54, Issue 3, 2013, Pages 397-401

  Heuveling, Derrek A ^a   De Bree, Remco ^a   Vugts, Danielle J ^a   Huisman, Marc C ^a   Giovannoni, Leonardo ^b   Hoekstra, Otto S ^a   Leemans, C René ^a   Neri, Dario ^c   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Philogen SpA   (Italy)

^c ETH ZURICH   (Switzerland)

Author keywords

Head and neck cancer; Immuno PET; Microdosing; Monoclonal antibody; Phase 0

Indexed keywords

F16SIP ANTIBODY I 124; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CASE REPORT; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG TOLERABILITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK SURGERY; HUMAN; HUMAN TISSUE; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; PROTEIN STRUCTURE, TERTIARY; RADIATION DOSAGE; RADIOPHARMACEUTICALS; TENASCIN; TISSUE DISTRIBUTION;

EID: 84874857624     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.111310     Document Type: Article

References (18)

1. Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11:9-22.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
3. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res. 2006;12: 3200-3208. (Pubitemid 43837370)
4. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer. 2005;5: 436-446. (Pubitemid 40791486)
5. Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer. 2002;102:75-85.
6. Eigentler TK, Weide B, De Braud F, et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res. 2011;17: 7732-7742.
7. Johannsen M, Spitaleri G, Curigliano G, et al. The tumour-targeting human L19- IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer. 2010;46:2926-2935.
8. Sauer S, Erba PA, Petrini M, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009;113:2265- 2274.
9. Schwager K, Villa A, Rösli C, Neri D, Rösli-Khabas M, Moser G. A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol. 2011;3:25.
10. Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov. 2003;2:233- 240. (Pubitemid 37361669)
11. Marchetti S, Schellens JHM. The impact of FDA and EMEA guidelines on drug development in relation to phase 0 trials. Br J Cancer. 2007;97:577-581. (Pubitemid 47339894)
12. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9: 203-214.
13. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates. Nat Rev Drug Discov. 2004;3:711-715. (Pubitemid 39173511)
14. Wagner CC, Langer O. Approaches using molecular imaging technology: use of PET in clinical microdose studies. Adv Drug Deliv Rev. 2011;63:539-546.
15. Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol. 2010;28:917- 924.
16. Visser GWM, Klok RP, Klein Gebbinck JW, Ter Linden T, Van Dongen GAMS, Molthoff CF. Optimal quality 131I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODOGEN. J Nucl Med. 2001;42:509-519. (Pubitemid 32207405)
17. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
18. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.